VDFA
NVCR icon

Vickerman & Driscoll Financial Advisors’s NovoCure NVCR Stock Holding History

Vickerman & Driscoll Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$5K – 96
2018
Q3 		$5K Hold
100
– – ﹤0.01% 107
2018
Q2 		$3K Hold
100
– – ﹤0.01% 108
2018
Q1 		$2K Hold
100
– – ﹤0.01% 109
2017
Q4 		$2K Buy
+100
New +$1.93K ﹤0.01% 107

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Vickerman & Driscoll Financial Advisors's NVCR Position: Q4 2018 in Review

Vickerman & Driscoll Financial Advisors sold out of NovoCure (NVCR) in Q4 2018, closing a stake of 100 shares — an estimated $5K sold.

Vickerman & Driscoll Financial Advisors first reported a position in NVCR in Q4 2017 and held it in 4 quarters. The position peaked at $5K in Q3 2018. 166 funds tracked by Wall St. Rank hold NVCR as of Q4 2018.

  • Vickerman & Driscoll Financial Advisors reported no remaining NovoCure position as of Q4 2018 after selling out during the quarter.
  • Vickerman & Driscoll Financial Advisors sold 100 NovoCure shares in Q4 2018, an estimated $5K.
  • Vickerman & Driscoll Financial Advisors first reported a position in NovoCure in Q4 2017 and held it in 4 quarters.
  • Vickerman & Driscoll Financial Advisors's NovoCure position peaked at $5K in Q3 2018.
  • 166 funds tracked by Wall St. Rank held NovoCure as of Q4 2018.

Based on Vickerman & Driscoll Financial Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.